Voisin Consulting Life Sciences webinar icon
Webinar

Patient access to Advanced Therapies in Europe 2009-2021: from early access failures to current challenges

Post thumbnail Patient access to Advanced Therapies in Europe 2009-2021: from early access failures to current challenges

The recent announcement of BlueBirdBio to wind down its European commercialisation efforts due to access and pricing challenges for its gene therapy products has put a new spotlight on the market access and payer environment for advanced therapies in Europe.

In this webinar VCLS market access experts will analyse the commercial failures of advanced therapies, discuss key HTA challenges for these products in European markets and how to plan ahead to overcome them.

Voisin Consulting Life Sciences download icon

Register to this webinar now

Patient access to Advanced Therapies in Europe 2009-2021: from early access failures to current challenges

Sep 23, 202116:00 CEST1 hour

Convert to my timezone

Featured Speakers

Gabrielle Nayroles
Gabrielle Nayroles, M.Sc.
Director, Market Access
As a Director in the Market Access team, Gabrielle is responsible for conducting market access analyses and providing recommendations and…
View profile
Henrike Granzow
Henrike Granzow, M.Sc.
Director, Market Access
As a Director in the Market Access Team, Henrike is responsible for developing successful market access and reimbursement strategies, on…
View profile
Emmanuelle Sabbah-Petrover
Emmanuelle Sabbah-Petrover, PhD
Director, Complex Biologics
As Director at Voisin Consulting Life Sciences, Emmanuelle manages projects involving cellular and gene-based medicinal products; from early stages of…
View profile